References
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- World Health Organization. Diabetes Fact Sheet: World Health Organization 2016. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. [Last accessed 5 July 2017]
- American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care 2016;39(Suppl 1):S1-S110
- Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
- Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ 2016;42:34-71
- Gonzalez J, Peyrot M, McCarl A, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008;31:2398-403
- Peyrot M, Rubin R, Kruger D, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:243-8
- Peyrot M, Barnett A, Meneghini L, et al. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) study. Diabetes Obes Metabol 2012;14:1081-7
- Peyrot M, Rubin R, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes 2010;4(Suppl 1):S11-S18
- Peyrot M, Rubin R, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national DAWN study. Diabetes Care 2005;28:2673-9
- Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 2008;34:511-17
- Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
- Peyrot M, Skovlund S. Willingness to initiate/intensify medications in the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) study. Late Breaking Abstract. American Diabetes Association Scientific Sessions, 2014
- Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 2014;5:225-42
- Perez-Nieves M, Kabul S, Desai U, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin 2016;32:669-80
- Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naive type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence 2015;9:1225-31
- Davies M, Storms S, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-8
- Mosenzon O, Raz I. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal–bolus regimen versus premix insulin analogs. When and for whom? Diabetes Care 2013;36(Suppl 2):S212-S18
- Perez-Nieves M, Ivanova JI, Hadjiyianni I, et al. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Curr Med Res Opin. 201710:1-25
- Rubin R, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
- Peyrot M, Rubin R. Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes. Diabetes Technol Therapeut 2011;13:43-8
- Ryan E, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32
- Wei W, Pan C, Xie L, et al. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract 2014;20:52-61
- Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8